Fibrosis biomarker assay

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9880177
SERIAL NO

15446070

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A method of bioassay for the quantification of biomarkers useful in the diagnosis of fibrosis disease and prognosis of its development, including biomarkers indicative of the risk of developing fibrosis after a chronic injury is provided. In particular, according to the present invention, biomarkers relating to degradation fragments of Collagen type I, III, IV, V, and VI, elastin, C-reactive protein, and proteoglycans including Biglycan, Decorin, Versican, and Perlecan are found to be useful.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NORDIC BIOSCIENCE A/S2730 HERLEV

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Karsdal, Morten A Copenhagen O, DK 13 44
Michaelsen, Natasha Barascuk Gentofte, DK 5 16
Oersnes-Leeming, Diana J Klampenborg, DK 2 6
Segovia-Silvestre, Antonio Copenhagen, DK 3 19
Skjot-Arkil, Helene Kolding, DK 3 13
Vassiliadis, Efstathios Hammel, DK 6 29
Veidal, Sanne S Olstykke, DK 4 23

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 30, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 30, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00